WO2007008704A2 - Melanocortin receptor ligands - Google Patents
Melanocortin receptor ligands Download PDFInfo
- Publication number
- WO2007008704A2 WO2007008704A2 PCT/US2006/026586 US2006026586W WO2007008704A2 WO 2007008704 A2 WO2007008704 A2 WO 2007008704A2 US 2006026586 W US2006026586 W US 2006026586W WO 2007008704 A2 WO2007008704 A2 WO 2007008704A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cys
- arg
- phe
- trp
- ala
- Prior art date
Links
- UPWXVZMGXHSGLC-STQMWFEESA-N CC([C@H](CCCCNC(C[C@@H](C(C)=O)NC)=O)NC)=O Chemical compound CC([C@H](CCCCNC(C[C@@H](C(C)=O)NC)=O)NC)=O UPWXVZMGXHSGLC-STQMWFEESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention is directed to peptides which are ligands of one or more of the melanocortin receptors (MC-R), the pharmaceutically-acceptable salts thereof, to methods of using such peptides to treat mammals and to useful pharmaceutical compositions comprising said peptides.
- M-R melanocortin receptors
- POMC pro-hormone proopiomelanocortin
- Melanocortins have been found in a wide variety of normal human tissues including the brain, adrenal, skin, testis, spleen, kidney, ovary, lung, thyroid, liver, colon, small intestine and pancreas (Tatro, J. B. et al., Endocrinol. 121:1900-1907 (1987); Mountjoy, K. G. et al., Science 257:1248-1251 (1992); Chhajlani, V. et al., FEBS Lett. 309:417-420 (1992); Gantz, I. et al. J. Biol. Chem. 268:8246-8250 (1993) and Gantz, I. et al., J. Biol. Chem. 268:15174-15179 (1993)).
- Melanocortin peptides have been shown to exhibit a wide variety of physiological activities including the control of behavior and memory, affecting neurotrophic and antipyretic properties, as well as affecting the modulation of the immune system. Aside from their well known effects on adrenal cortical functions (adrenocorticotropic hormone, ACTH) and on melanocytes (melanocyte stimulating hormone, MSH), melanocortins have also been shown to control the cardiovascular system, analgesia, thermoregulation and the release of other neurohumoral agents including prolactin, luteinizing hormone and biogenic amines (De Wied, D. et al v Methods Achiev. Exp. Pathol. 15:167-199 (1991); De Wied, D.
- melanocortin receptors Five melanocortin receptors (MC-R) have been characterized to date. These include melanocyte-spedfic receptor (MCl-R), corticoadrenal-specific ACTH receptor (MC2-R), melacortin-3 (MC3-R), melanocortin-4 (MC4-R) and melanocortin-5 receptor (MC5-R).
- MSH melanocyte stimulating hormones
- MCl-R known in the art as Melanocyte Stimulating Hormone Receptor (MSH-R), Melanotropin Receptor or Melanocortin-1 Receptor, is a 315 amino acid transmembrane protein belonging to the family of G-Protein coupled receptors. MCl-R is a receptor for both MSH and ACTH. The activity of MCl-R is mediated by G-proteins which activate adenylate cyclase.
- MCl-R receptors are found in melanocytes and corticoadrenal tissue as well as various other tissues such as adrenal gland, leukocytes, lung, lymph node, ovary, testis, pituitary, placenta, spleen and uterus.
- MC2-R also called Adrenocorticotropic hormone receptor (ACTH-R)
- ACTH-R Adrenocorticotropic hormone receptor
- MC2-R mediates the corticotrophic effect of ACTH.
- MC3-R is a 360 AA protein found in brain tissue; in mice and rats MC3-R is a 323 AA protein.
- MC4-R is a 332 amino acid transmembrane protein which is also expressed in brain as well as placental and gut tissues.
- MC5-R is a 325 amino acid transmembrane protein expressed in the adrenals, stomach, lung and spleen and very low levels in the brain.
- MC5-R is also expressed in the three layers of adrenal cortex, predominantly in the aldosterone-producing zona glomerulosa cells.
- MCl-R is a G-protein coupled receptor that regulates pigmentation in response to ⁇ -MSH, a potent agonist of MCl-R.
- Agonism of the MCl-R receptor results in stimulation of the melanocytes which causes eumelanin and increases the risk for cancer of the skin.
- Agonism of MCl-R can also have neurological effects. Stimulation of MC2-R activity can result in carcinoma of adrenal tissue.
- Recent pharmacological confirmation has established that central MC4-R receptors are the prime mediators of the anorexic and orexigenic effects reported for melanocortin agonists and antagonists, respectively.
- the effects of agonism of the MC3-R and MC5-R are not yet known.
- MC-R melanocortin receptors
- Both genetic and pharmacological evidence points toward central MC4-R receptors as the principal target (Giraudo, S. Q. et al, Brain Res., 809:302-306 (1998); Farooqi, I. S. et al., NE J Med., 348:1085-1095 (2003); MacNeil, D. J. et al., Eu. J. Pharm., 44:141-157 (2002); MacNeil, D. J. et al., Eu. J. Pharm., 450:93-109 (2002); Kask, A. et al., NeuroReport, 10:707-711 (1999)).
- the current progress with receptor- selective agonists and antagonists evidences the therapeutic potential of melanocortin receptor activation, particularly MC4-R.
- Agonist, antagonist or other ligand compounds activating one or more melanocortin receptor would be useful for treating a wide variety of indications in a subject in need thereof or at risk thereof including acute and chronic inflammatory diseases such as general inflammation (U.S. Patent No. 6,613,874; Catania, A. et al., Pharm. Rev., 56:1-29 (2004)), inflammatory bowel disease (U.S. Patent No. 6,713,487; Catania, A. et al., Pharm. Rev., 56:1-29 (2004)), brain inflammation (Catania, A. et al., Pharm. Rev., 56:1-29 (2004)), sepsis (U.S. Patent No. 6,613,874; U.S. Patent No.
- Drugs 2:1064- 1069 (2001)), and multiple sclerosis ((U.S. Patent No. 6,713,487); metabolic diseases and medical conditions accompanied by weight gain such as obesity (U.S. Patent No. 1,613,874; U.S. Patent No. 6,600,015; Fehm, H. L. et al., J. Clin. Endo. & Metab., 16:1144-1148 (2001); Hansen, M. J. et al., Brain Res., 1039:137-145 (2005); Ye, Z. et al., 'eptides, 26:2017-2025 (2005); Farooqi, I. S.
- pulmonary diseases or conditions such as acute respiratory distress syndrome (U.S. Patent No. 6,350,430; Catania, A. et al., Pharm. Rev., 56:1-29 (2004)), chronic obstructive pulmonary disease (U.S. Patent No. 6,713,487), asthma (U.S. Patent No. 6,713,487) and pulmonary fibrosis; to enhance immune tolerance (Luger, T. A. et al., Pathobiology, 67:318-321 (1999)) and to combat assaults to the immune system such as those associated with certain allergies (U.S. Patent No. 6,713,487) or organ transplant rejection (U.S. Patent No.
- Ligand compounds activating one or more melanocortin receptor would be useful for modulating a wide variety of normalizing or homeostatic activities in a subject in need thereof including thyroxin release (U.S. Patent No. 6,613,874), aldosterone synthesis and release (U.S. Patent No. 6,613,874), body temperature (U.S. Patent No. 6,613,874), blood pressure (U.S. Patent No. 6,613,874), heart rate (U.S. Patent No. 6,613,874), vascular tone (U.S. Patent No. 6,613,874), brain blood flow (U.S. Patent No. 6,613,874), blood glucose levels (U.S. Patent No.
- Patent No. 6,639,123 and nerve growth (U.S. Patent No. 6,613,874) as well as modulating motivation (U.S. Patent No. 6,613,874), learning (U.S. Patent No. 6,613,874) and other behaviors (U.S. Patent No. 6,613,874). It is, therefore, an objective of the present invention to provide ligands for the melanocortin receptors which exhibit greater stability and selectivity for melanocortin receptors than native melanocortin receptor ligands.
- the present invention is directed to a compound according formula (I):
- a 1 is Ace, HN-(CH2)m-C(O), L- or D-amino acid, or deleted;
- a 2 is Cys, D-Cys, hCys, D-hCys, Pen, D-Pen, Asp, or GIu;
- a 3 is GIy, Ala, ⁇ -A ⁇ a, Gaba, Aib, D-amino acid, or deleted;
- a 4 is His, 2-Pal, 3-Pal, 4-Pal, Taz, 2-Thi, 3-Thi, or (X ⁇ X ⁇ X ⁇ Phe;
- a 5 is D-Phe, D-I-NaI, D-2-Nal, D-Trp, D-BaI, D- ⁇ XVW ⁇ Phe, L-Phe or D-(Et)Tyr;
- a 6 is Arg, hArg, Dab, Dap, Lys, Om, or HN-CH((CH 2 )n-N(R 4 R 5 ))-C(O);
- a 7 is Trp, 1-Nal, 2-Nal, BaI 7 Bip, D-Trp, D-I-NaI, D-2-Nal, D-BaI or D-Bip;
- a 8 is GIy, D-AIa, Ace, Ala, ⁇ -Ala, Gaba, Apn, Ahx, Aha, HN-(CHa) 5 -C(O), or deleted;
- a 9 is Cys, D-Cys, hCys, D-hCys, Pen, D-Pen, Dab, Dap, Om, or Lys;
- a 10 is Ace, HN-(OHb)I-C(O), L- or D-amino acid, or deleted;
- R 1 is -OH, or -NH 2 ; each of R 2 and R 3 is independently for each occurrence selected from the group consisting of H, (G-C3o)alkyl, (G-Gojheteroalkyl, (Ci-C3o)acyl, (C2-C3o)alkenyl, (C2-C3o)alkynyl, aryl(G-C3o)alkyl, aryl(Ci-C3o)acyl, substituted (Ci-C3o)alkyl, substituted (Ci-C3o)heteroalkyl, substituted (Ci-C3o)acyl, substituted (C2-C3o)alkenyl, substituted (C2-C3o)alkynyl, substituted aryl(G-C3o)alkyl, and substituted aryl(Ci-
- R 4 and R 5 each is, independently for each occurrence, H, (Ci-C4o)alkyl, (G- C4o)heteroalkyl, (G ⁇ C4o)acyl, (C2-Qo)alkenyl, (C2-C4o)alkynyl, aryl(G-Qo)alkyl, iryl(Ci-C4o)acyl, substituted (Ci-C4o)alkyl, substituted (Ci-Qo)heteroalkyl, substituted Ci-Gio)acyl, substituted (C2-C4o)alkenyl / substituted (C2-Qo)alkynyl, substituted iryl(Ci-C4o)alkyl, substituted aryl(G-Go)acyl, (Ci-C4o)alkylsulfonyl, or -C(NH)-NHz; m is, independently for each occurrence, 1, 2, 3, 4, 5, 6 or 7; n is
- X 1 , X 2 , X 3 , X 4 , and X 5 each is, independently for each occurrence, H, F, Cl, Br, I, (Ci-io)alkyl, substituted (Ci-io)alkyl, (C2-io)alkenyl, substituted (C2-io)alkenyl, (C2-io)alkynyl, substituted (C2-io)alkynyl, aryl, substituted aryl, OH, NH2, NO2, or CN; provided that
- R 4 is (Ci-Oo)acyl, aryl(Ci-Cio)acyl, substituted (Ci-C4o)acyl, substituted aryl(Ci-Oo)acyl, (Ci-Gio)alkylsulfonyl, or -C(NH)-NH 2
- R 5 is H or (Ci-G ⁇ o)alkyl, (Ci-Gio)heteroalkyl, (C ⁇ -G ⁇ lkenyl, (C 2 -C4o)alkynyl, aryl(Ci-
- R 2 is (Ci-C3o)acyl, aryl(Ci-C3o)acyl, substituted (Ci-C3o)acyl, or substituted aryl(Ci-C 3 o)acyl
- R 3 is H, (Ci-C3o)alkyl, (Ci-C 3 o)heteroalkyl
- a preferred group of compounds of the immediate foregoing formula is where A 1 is A6c, Gaba, NIe, Met, Phe, D-Phe, D-2-Nal, hPhe, Chg, D-Chg, Cha, hCha, hPro, hLeu, Nip,/-hMet, or Oic;
- a 2 is Cys, D-Cys, hCys, D-hCys, Pen, D-Pen, Asp, or GIu;
- a 3 is GIy, Ala, D-AIa, D-GIu, ⁇ -Ala, Gaba, Aib, or deleted;
- a 4 is His
- a 5 is D-Phe, D-I-NaI, D-2-Nal, D-Trp, D-BaI, or D-(Et)Tyr;
- a 6 is Arg, or hArg
- a 7 is Trp, Bip, D-Trp, 1-Nal, or 2-Nal;
- a 8 is A6c, Ala, ⁇ -Ala, Gaba, Apn, or Ahx;
- a 9 is Cys, D-Cys, hCys, D-hCys, Pen, D-Pen, or Lys;
- a 10 is Thr, or deleted or a pharmaceutically acceptable salt thereof.
- R 2 and R 3 each is, independently, H, acyl, n-propanoyl, or n- butanoyl or a pharmaceutically acceptable salt thereof.
- a more preferred compound of formula (I) is where said compound is of the formula:
- a 1 is Ace, Arg, D-Arg, Cha, D-Cha, hCha, Chg, D-Chg, Gaba, He, Leu, hLeu,
- a 2 is Cys, D-Cys, Pen or Asp;
- a 3 is GIy, Ala, ⁇ -Ala, Gaba, Aib, D-AIa, D-Abu, D-Cha, D-IIe, D-Leu, D-TIe, D-VaI or deleted;
- a 4 is His or 3-Pal
- a 5 is D-Phe, D-2-Nal or D-(Et)Tyr;
- a 6 is Arg or hArg
- a 7 is Trp, 1-Nal, 2-Nal, BaI, Bip or D-Trp;
- a 8 is GIy, D-AIa, Ace, Ala, ⁇ -Ala, Gaba, Apn, Ahx, Aha or deleted;
- a 9 is Cys, D-Cys, Pen or Lys
- a 10 is Thr or deleted; wherein at least one of A 3 or A 8 is deleted, but not both, or a pharmaceutically acceptable salt thereof.
- More preferred compounds of the immediately foregoing group of compounds is where said compound is of the formula: Ac-Nle-c(Asp-His-D-Phe-Arg-Trp- ⁇ -Ala-Lys)-NH 2 ; Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-A6c-Lys)-NH2; Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-NH 2 ; D-Phe-c(Cys-His-D-Phe-Arg-Trp-Ala-D-Cys)-Thr-NH2; D-Phe-c(Cys-His-D-Phe-Arg-Trp- ⁇ -Ala-D-Cys)-Thr-NH 2 ; D-Phe-c(Cys-His-D-Phe-Arg-Trp- ⁇ -Ala-D-Cys)
- a 1 is Arg, D-Arg, Cha, hCha, Ch g/ D-Chg, He, Leu, 2-NaI 7 NIe, Phe, D-Phe, hPhe, VaI or deleted;
- a 2 is Cys, Pen or Asp
- a 3 is D-AIa, D-Abu, D-Cha, D-IIe, D-Leu, D-TIe, D-VaI or deleted;
- a 4 is His or 3-Pal
- a 5 is D-Phe, D-2-Nal or D-(Et)Tyr;
- a 6 is Arg or hArg
- a 7 is Trp, 2-Nal, BaI, Bip or D-Trp;
- a 8 is GIy, Ala, ⁇ -Ala, Gaba, Apn, Ahx, or deleted;
- a 9 is Cys, D-Cys, Pen or Lys
- a 10 is Thr or deleted; each of R 2 and R 3 is independently selected from the group consisting of H or acyl; or a pharmaceutically acceptable salt thereof.
- a more preferred compound of formula (I) is where said compound is of the formula:
- a 1 is Arg, D-Arg, hArg or D-hArg; or a pharmaceutically acceptable salt thereof.
- a more preferred compound of the immediately foregoing group of compounds is where said compound is of the formula:
- a 2 is Cys, D-Cys, hCys, D-hCys, Pen, D-Pen, Asp, or GIu;
- a 3 is GIy, Ala, D-AIa, D-GIu, ⁇ -Ala, Gaba, Aib, or deleted;
- a 4 is His
- a 5 is D-Phe, D-I-NaI, D-2-Nal, D-Trp, D-BaI, or D-(Et)Tyr;
- a 6 is Arg, or hArg;
- a 7 is Trp, Bip, D-Trp, 1-NaI 7 or 2-Nal;
- a 8 is A6c, Ala, ⁇ -Ala, Gaba, Apn, or Ahx;
- a 9 is Cys, D-Cys, hCys, D-hCys, Pen, D-Pen, or Lys;
- a 10 is Thr, or deleted; or a pharmaceutically acceptable salt thereof.
- R 2 and R 3 each is, independently, H, acyl, n-propanoyl, or n- butanoyl or a pharmaceutically acceptable salt thereof.
- a more preferred compound of the immediately foregoing group of compounds is where said compound is of the formula:
- a 2 is Cys or Asp
- a 3 is D-AIa or deleted
- a 4 is His
- a 5 is D-Phe or D-2-Nal
- a 6 is Arg
- a 7 is Trp
- a 8 is Ala, Gaba or deleted
- a 9 is Cys, Pen or Lys
- a 10 is deleted; or a pharmaceutically acceptable salt thereof.
- R 2 and R 3 each is, independently, H or acyl; or a pharmaceutically acceptable salt thereof.
- the present invention is directed to a compound according formula (II):
- a 1 is NIe or deleted;
- a 2 is Cys or Asp;
- a 3 is GIu or D-AIa;
- a 4 is His;
- a 5 is D-Phe;
- a 6 is Arg
- a 7 is Trp, 2-Nal or BaI
- a 8 is GIy, Ala, D-AIa, ⁇ -Ala, Gaba or Apn;
- a 9 is Cys or Lys; each of R 2 and R 3 is independently selected from the group consisting of H or provided that
- Another more preferred compound of formula (I) or formula (II) is each of the compounds that are specifically enumerated herein below in the Examples section of the present disclosure, or a pharmaceutically acceptable salt thereof.
- the present invention provides a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, wherein said compound is a selective melanocortin-4 receptor agonist.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, wherein said compound is a selective melanocortin 4 receptor agonist with a functional activity characterized by an ECso at least 15- fold more selective for the human melanocortin 4 receptor than for the human melanocortin 1 receptor, the human melanocortin 3 receptor and the human melanocortin 5 receptor.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, wherein said compound is a selective melanocortin 4 receptor agonist with a functional activity characterized by an ECso at least 17-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 3 receptor, an ECso at least 90-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 3 receptor, an ECso at least 200-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 5 receptor, or an ECso at least 3000-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 5 receptor.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, useful for treating an acute or chronic inflammatory disease or medical condition such as general inflammation, inflammatory bowel disease, brain inflammation, sepsis and septic shock.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, useful for treating a disease or medical condition with an autoimmune component such as rheumatoid arthritis, gouty arthritis and multiple sclerosis.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, useful for treating a metabolic disease or medical condition accompanied by weight gain such as obesity, feeding disorders and Prader-Willi Syndrome.
- a metabolic disease or medical condition accompanied by weight gain such as obesity, feeding disorders and Prader-Willi Syndrome.
- the disease or condition treated is obesity.
- the disease or condition treated is a feeding disorder.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, useful for decreasing food intake, for decreasing body weight or a combination thereof.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising an effective amount of a compound of formula (I) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, which is useful for diminishing food intake, decreasing body weight, or a combination thereof, wherein the active ingredient is one or more of the following compounds: Ac-Nle-c(Cys-His-D-Phe-Arg- Trp-Gaba-Pen)-NH 2 , Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2, Ac-D-Arg- c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH 2 , Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg- Trp-Pen)-NH2 / Ac-Nle-c(Cys-D
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising an effective amount of a compound of formula (I) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, which is useful for diminishing food intake, decreasing body weight, or a combination thereof, wherein the active ingredient is_Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising an effective amount of a compound of formula (I) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, which is useful for diminishing food intake, decreasing body weight, or a combination thereof, wherein the active ingredient is Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NU2.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising an effective amount of a compound of formula (I) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, which is useful for diminishing food intake, decreasing body weight, or a combination thereof, wherein the active ingredient is Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2.
- the present invention provides a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically-acceptable carrier or diluent, which is useful for decreasing appetite without compromising body weight.
- the present invention provides a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically- acceptable carrier or diluent, useful for decreasing food consumption while increasing body weight.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, useful for treating a metabolic disease or medical condition accompanied by weight loss such as anorexia, bulimia, AIDS wasting, cachexia, cancer cachexia and wasting in frail elderly.
- the disease or condition treated is anorexia.
- the disease or condition treated is bulimia.
- the disease or condition treated is AIDS wasting or wasting in frail elderly.
- the disease or condition treated is cachexia or cancer cachexia.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, useful for treating a neoplastic disease or medical condition such as skin cancer and cancer cachexia.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, useful for treating a reproductive or sexual medical condition such as endometriosis, uterine bleeding, sexual dysfunction, erectile dysfunction and decreased sexual response in females.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, useful for treating a disease or medical condition resulting from treatment or insult to an organism such as organ transplant rejection, ischemia and reperfusion injury, wounding and spinal cord injury, and weight loss due to a medical procedure selected from the group consisting of chemotherapy, radiation therapy, temporary or permanent immobilization and dialysis.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, useful for treating a cardiovascular disease or medical condition such as hemorrhagic shock, cardiogenic shock, hypovolemic shock, cardiovascular disorders and cardiac cachexia.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, useful for treating a pulmonary disease or medical condition such as acute respiratory distress syndrome, pulmonary fibrosis, chronic obstructive pulmonary disease and asthma.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, useful for enhancing immune tolerance and treating allergies.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, useful for treating a dermatological disease or medical condition such as psoriasis, skin pigmentation depletion, acne and keloid formation.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically-acceptable carrier or diluent, useful for treating a behavioral or central nervous system or neuronal disease or medical condition such as anxiety, depression, memory dysfunction and neuropathic pain.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically-acceptable carrier or diluent, useful for treating a renal disease or medical condition such as renal cachexia and natriuresis.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically-acceptable carrier or diluent, useful for modulating ovarian weight, placental development, prolactin secretion, FSH secretion, intrauterine fetal growth, parturition, spermatogenesis, thyroxin release, aldosterone synthesis and release, body temperature, blood pressure, heart rate, vascular tone, brain blood flow, blood glucose levels, sebum secretion, pheromone secretion, motivation, learning and behavior, pain perception, neuroprotection and nerve growth.
- a pharmaceutically-acceptable carrier or diluent useful for modulating ovarian weight, placental development, prolactin secretion, FSH secretion, intrauterine fetal growth, parturition, spermatogenesis, thyroxin release, al
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically-acceptable carrier or diluent, useful for modulating bone metabolism, bone formation and bone development.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically-acceptable carrier or diluent, useful for inhibiting alcohol consumption, for reducing alcohol consumption, for treating alcoholism, or for treating alcohol abuse.
- the compound of the composition useful for inhibiting alcohol consumption, for reducing alcohol consumption, for treating alcoholism, or for treating alcohol abuse is a selective melanocortin 4 receptor agonist.
- the compound of the composition useful for inhibiting alcohol consumption is a selective melanocortin 4 receptor agonist, or a pharmaceutically acceptable salt thereof, with a functional activity characterized by an EC50 at least 15-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 1 receptor, the human melanocortin 3 receptor and the human melanocortin 5 receptor.
- the compound of the composition useful for inhibiting alcohol consumption is a selective melanocortin 4 receptor agonist, or a pharmaceutically acceptable salt thereof, with a functional activity characterized by an ECso at least 17-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 3 receptor, an ECso at least 90-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 3 receptor, an ECso at least 200-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 5 receptor, or an ECso at least 3000-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 5 receptor.
- the present invention provides the use of a therapeutically effective amount of a melanocortin 4 receptor agonist compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament useful for inhibiting alcohol consumption, for reducing alcohol consumption, for treating alcoholism, or for treating alcohol abuse in a subject in need of such treatment.
- the present invention provides a method of eliciting an agonist or an antagonist effect from a melanocortin receptor in a subject in need thereof which comprises administering to said subject an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.
- the present invention provides a method of eliciting an agonist or an antagonist effect from a melanocortin receptor in a subject in need thereof which comprises administering to said subject an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, wherein said compound is a selective melanocortin 4 receptor agonist.
- the present invention provides a method of eliciting an agonist or an antagonist effect from a melanocortin receptor in a subject in need thereof which comprises administering to said subject an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, wherein said compound is a selective melanocortin 4 receptor agonist with a functional activity characterized by an EC so at least 15- fold more selective for the human melanocortin 4 receptor than for the human melanocortin 1 receptor, the human melanocortin 3 receptor and the human melanocortin 5 receptor.
- the present invention provides a method of eliciting an agonist or an antagonist effect from a melanocortin receptor in a subject in need thereof which comprises administering to said subject an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, wherein said compound is a selective melanocortin 4 receptor agonist with a functional activity characterized by an ECso at least 17-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 3 receptor, an ECso at least 90-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 3 receptor, an ECso at least 200-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 5 receptor, or an ECso at least 3000-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 5 receptor.
- the present invention provides a method of treating an acute or chronic inflammatory disease or medical condition such as general inflammation, inflammatory bowel disease, brain inflammation, sepsis and septic shock by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.
- an acute or chronic inflammatory disease or medical condition such as general inflammation, inflammatory bowel disease, brain inflammation, sepsis and septic shock by eliciting an agonist or antagonist effect from a melanocortin receptor
- the present invention provides a method of treating a disease or medical condition with an autoimmune component such as rheumatoid arthritis, gouty arthritis and multiple sclerosis by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.
- an autoimmune component such as rheumatoid arthritis, gouty arthritis and multiple sclerosis
- the present invention provides a method of treating a metabolic disease or medical condition accompanied by weight gain such as obesity, feeding disorders and Prader-Willi Syndrome by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.
- a metabolic disease or medical condition accompanied by weight gain such as obesity, feeding disorders and Prader-Willi Syndrome by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.
- the disease or condition treated is obesity.
- the disease or condition treated is a feeding disorder.
- the present invention provides a method of decreasing food intake, decreasing body weight or a combination thereof, by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.
- the present invention provides a method of decreasing food intake, decreasing body weight or a combination thereof, by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein said compound is Ac-Nle-c(Cys- His-D-Phe-Arg-Trp-Gaba-Pen)-NH 2 , Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)- NH2, Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH 2 , Ac-D-Arg-c(Cys-D-Ala- His-D-Phe-Arg-Trp-Pen)-NH 2 , Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)
- the present invention provides a method of decreasing food intake, decreasing body weight or a combination thereof, by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein said compound is Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)- NH 2 .
- the present invention provides a method of decreasing food intake, decreasing body weight or a combination thereof, by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein said compound is Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)- NH 2 .
- the present invention provides a method of decreasing food intake, decreasing body weight or a combination thereof, by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein said compound is Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-
- the present invention provides a method of decreasing appetite without compromising body weight by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.
- the present invention provides a method of decreasing food consumption while increasing body weight by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.
- the present invention provides a method of treating a metabolic disease or medical condition accompanied by weight loss such as anorexia, bulimia, AIDS wasting, cachexia, cancer cachexia and wasting in frail elderly by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.
- a metabolic disease or medical condition accompanied by weight loss such as anorexia, bulimia, AIDS wasting, cachexia, cancer cachexia and wasting in frail elderly by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.
- the foregoing method is used to treat anorexia.
- the foregoing method is used to treat bulimia.
- the foregoing method is used to treat
- the present invention provides a method of treating a neoplastic disease or medical condition such as skin cancer and cancer cachexia by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.
- the present invention provides a method of treating a reproductive or sexual medical condition such as endometriosis, uterine bleeding, sexual dysfunction, erectile dysfunction and decreased sexual response in females by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.
- the present invention provides a method of treating a disease or medical condition resulting from treatment or insult to an organism such as organ transplant rejection, ischemia and reperfusion injury, wounding and spinal cord injury, and weight loss due to a medical procedure selected from the group consisting of chemotherapy, radiation therapy, temporary or permanent immobilization and dialysis by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.
- the present invention provides a method of treating a cardiovascular disease or medical condition such as hemorrhagic shock, cardiogenic shock, hypovolemic shock, cardiovascular disorders and cardiac cachexia by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.
- a cardiovascular disease or medical condition such as hemorrhagic shock, cardiogenic shock, hypovolemic shock, cardiovascular disorders and cardiac cachexia by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.
- the present invention provides a method of treating a pulmonary disease or medical condition such as acute respiratory distress syndrome, pulmonary fibrosis, chronic obstructive pulmonary disease and asthma by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.
- a pulmonary disease or medical condition such as acute respiratory distress syndrome, pulmonary fibrosis, chronic obstructive pulmonary disease and asthma by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.
- the present invention provides a method of enhancing immune tolerance or treating allergies by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.
- the present invention provides a method of treating dermatological disease or medical condition such as psoriasis, skin pigmentation depletion, acne and keloid formation by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof,
- the present invention provides a method of treating a behavioral or central nervous system or neuronal disease or medical condition such as anxiety, depression, memory dysfunction and neuropathic pain by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.
- the present invention provides a method of treating a renal disease or medical condition such as renal cachexia and natriuresis by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.
- the present invention provides a method of modulating a normalizing or homeostatic activity such as ovarian weight, placental development, prolactin secretion, FSH secretion, intrauterine fetal growth, parturition, spermatogenesis, thyroxin release, aldosterone synthesis and release, body temperature, blood pressure, heart rate, vascular tone, brain blood flow, blood glucose levels, sebum secretion, pheromone secretion, motivation, learning and behavior, pain perception, neuroprotection and nerve growth by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.
- a normalizing or homeostatic activity such as ovarian weight, placental development, prolactin secretion, FSH secretion, intrauterine fetal growth, parturition, spermatogenesis, thyroxin release, al
- the present invention provides a method of modulating a normalizing or homeostatic activity such as bone metabolism, bone formation and bone development by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.
- the present invention provides a method of inhibiting alcohol consumption, for reducing alcohol consumption, for treating alcoholism, or for treating alcohol abuse by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.
- the compound is a selective melanocortin 4 receptor agonist.
- the compound of the composition useful for inhibiting alcohol consumption is a selective melanocortin 4 receptor agonist, or a pharmaceutically acceptable salt thereof, with a functional activity characterized by an ECso at least 15- fold more selective for the human melanocortin 4 receptor than for the human melanocortin 1 receptor, the human melanocortin 3 receptor and the human melanocortin 5 receptor.
- the compound of the composition useful for inhibiting alcohol consumption is a selective melanocortin 4 receptor agonist, or a pharmaceutically acceptable salt thereof, with a functional activity characterized by an ECso at least 17-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 3 receptor, an ECso at least 90-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 3 receptor, an ECso at least 200-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 5 receptor, or an ECso at least 3000-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 5 receptor.
- the present invention provides the use of a therapeutically effective amount of a melanocortin 4 receptor agonist or antagonist compound according formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament useful to treat a disease and/or medical condition selected from the group consisting of acute and chronic inflammatory diseases such as general inflammation, inflammatory bowel disease, brain inflammation, sepsis and septic shock; diseases with an autoimmune component such as rheumatoid arthritis, gouty arthritis and multiple sclerosis; metabolic diseases and medical disorders accompanied by weight gain such as obesity, feeding disorders and Prader-Willi Syndrome; metabolic diseases and medical disorders accompanied by weight loss such as anorexia, bulimia, AIDS wasting, cachexia, cancer cachexia and wasting in frail elderly; diabetes, diabetalogical related conditions and complications of diabetes such as retinopathy; neoplastic proliferation such as skin cancer and prostate cancer; reproductive or sexual medical conditions such as endometrio
- the present invention provides the use of a therapeutically effective amount of a melanocortin 4 receptor agonist or antagonist compound according formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament useful to modulate normalizing or homeostatic activities such as ovarian weight, placental development, prolactin secretion, FSH secretion, intrauterine fetal growth, parturition, spermatogenesis, thyroxin release, aldosterone synthesis and release, body temperature, blood pressure, heart rate, vascular tone, brain blood flow, blood glucose levels, sebum secretion, pheromone secretion, motivation, learning and behavior, pain perception, neuroprotection, nerve growth, bone metabolism, bone formation and bone development.
- a medicament useful to modulate normalizing or homeostatic activities such as ovarian weight, placental development, prolactin secretion, FSH secretion, intrauterine fetal growth, parturition, sper
- the compounds of formulae (I) or (II) are ligands for at least one of the melanocortin receptors (MCl-R, MC2-R, MC3-R, MC4-R and MC5-R) and a selection thereof were tested for their ability to act as a ligand in the in vitro assay described below.
- Figure IA Mean difference in food consumed from vehicle in fasted rats 6 hours after administration of 100 nmole/Kg of selected compounds.
- Figure IB Mean difference in food consumed from vehicle in fasted rats 6 hours after administration of 500 nmole/Kg of selected compounds.
- Figure 2A Cumulative difference in mean food intake from vehicle in rats after administration of various concentrations of Compound A.
- Figure 2B Cumulative mean body weight difference from vehicle in rats after administration of various concentrations of Compound A.
- Figure 3A Cumulative difference in mean food intake from vehicle in rats after administration of selected compounds.
- Figure 3B Cumulative mean body weight difference from vehicle in rats after administration of selected compounds.
- Figure 4A Cumulative difference in mean food intake from vehicle in rats after administration of selected compounds.
- Figure 4B Cumulative mean body weight difference from vehicle in rats after administration of selected compounds. DETAILED DESCRIPTION OF THE INVENTTnN
- Bip 4 / 4'-biphenylalanine represented by the structure
- D-(Et)Tyr has a structure of
- Dmab 4- ⁇ N-(l-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-methylbutyl) amino ⁇ benzyl
- HOBt 1 -hy droxy-benzotriazole
- TIS triisopropylsilane
- TFFH tetramethylfluoroforamidinium hexafluorophosphate
- NH2 in e.g., Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)- NHz, indicates that the C-terminus of the peptide is amidated.
- Ac-Nle-c(Cys-D-Ala- His-D-Phe-Arg-Trp-Cys), or alternatively Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp- Cys)- OH indicates that the C-terminus is the free acid.
- Acyl refers to R" -C(O)-, where R" is H, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl, aryl, alkylaryl, or substituted alklyaryl, and is indicated in the general formula of a particular embodiment as "Ac”.
- Alkyl refers to a hydrocarbon group containing one or more carbon atoms, where multiple carbon atoms if present are joined by single bonds.
- the alkyl hydrocarbon group may be straight-chain or contain one or more branches or cyclic groups.
- Hydroalkyl refers to an alkyl group wherein one or more hydrogen atoms of the hydrocarbon group are substituted with one or more hydroxy radicals, such as hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl and the like.
- Substituted alkyl refers to an alkyl wherein one or more hydrogen atoms of the hydrocarbon group are replaced with one or more substituents selected from the group consisting of halogen, (i.e., fluorine, chlorine, bromine, and iodine), -OH, -CN, -SH, -NH>, -NHCH3, -NO2, and -Ci-20 alkyl, wherein said -Ci-20 alkyl optionally may be substituted with one or more substituents selected, independently for each occurrence, from the group consisting of halogens, -CF3, -OCH3, -OCF3, and -(CHz)(WO-COOH.
- halogen i.e., fluorine, chlorine, bromine, and iodine
- -OH i.e., fluorine, chlorine, bromine, and iodine
- -OH i.e., fluorine, chlorine, bromine, and iod
- substituents are present.
- the presence of -(CH2)o-2o-COOH results in the production of an alkyl acid.
- alkyl acids containing, or consisting of, -(CH2)o-2o-COOH include 2-norbornane acetic acid, tert-butyric acid, 3-cyclopentyl propionic acid, and the like.
- halo encompasses fluoro, chloro, bromo and iodo.
- Heteroalkyl refers to an alkyl wherein one of more of the carbon atoms in the hydrocarbon group is replaced with one or more of the following groups: amino, amido, -O-, -S- or carbonyl. In different embodiments 1 or 2 heteroatoms are present.
- Substituted heteroalkyl refers to a heteroalkyl wherein one or more hydrogen atoms of the hydrocarbon group are replaced with one or more substituents selected from the group consisting of halogen, (i.e., fluorine, chlorine, bromine, and iodine), -OH, -CN, -SH, -NH 2 , -NHCH 3 , -NO2, and -Ci-20 alkyl, wherein said -Ci-20 alkyl optionally may be substituted with one or more substituents selected, independently for each occurrence, from the group consisting of halogens, -CF3, -OCH3, -OCF3, and -(CH 2 )o-2o-COOH. In different embodiments 1, 2, 3 or 4 substituents are present.
- halogen i.e., fluorine, chlorine, bromine, and iodine
- -OH i.e., fluorine, chlorine, bromine, and iodine
- alkenyl refers to a hydrocarbon group made up of two or more carbons where one or more carbon-carbon double bonds are present.
- the alkenyl hydrocarbon group may, be straight-chain or contain one or more branches or cyclic groups.
- Substituted alkenyl refers to an alkenyl wherein one or more hydrogens are replaced with one or more substituents selected from the group consisting of halogen (i.e., fluorine, chlorine, bromine, and iodine), -OH, -CN, -SH, -NH2, -NHCH 3 , -NO2, and -Ci-20 alkyl, wherein said -Ci-20 alkyl optionally may be substituted with one or more substituents selected, independently for each occurrence, from the group consisting of halogens, -CF 3 , -OCH3, -OCF3, and -(CH 2 )(Mo-COOH. In different embodiments 1, 2, 3 or 4 substituents are present.
- halogen i.e., fluorine, chlorine, bromine, and iodine
- -OH i.e., fluorine, chlorine, bromine, and iodine
- -OH i.e.,
- Aryl refers to an optionally substituted aromatic group with at least one ring having a conjugated pi-electron system, containing up to three conjugated or fused ring systems.
- Aryl includes carbocyclic aryl, heterocyclic aryl and biaryl groups.
- the aryl is a 5- or 6-membered ring.
- Preferred atoms for a heterocyclic aryl are one or more sulfur, oxygen, and/or nitrogen.
- Non-limiting examples of aryl include phenyl, 1-naphthyl, 2-naphthyl, indole, quinoline, 2-imidazole, 9-anthracene, and the like.
- Aryl substituents are selected from the group consisting of -Ci-20 alkyl, -Ci-20 alkoxy, halogen (i.e., fluorine, chlorine, bromine, and iodine), -OH, -CN, -SH, -NH 2 , -NO2, -Ci-20 alkyl substituted with halogens, -CF 3 , -OCF3, and -(CHb)(MO-COOH.
- the aryl contains 0, 1, 2, 3, or 4 substituents.
- Alkylaryl refers to an “alkyl” joined to an “aryl”.
- (Ci-Ci2)hydrocarbon moiety encompasses alkyl, alkenyl and alkynyl and in the case of alkenyl and alkynyl there is C2-C12.
- normalizing functions or activities refers to those types of functions which may be considered to be involved in normal body function or homeostasis of an organism. Such functions include but are not limited to activities and functions affecting body temperature, blood pressure, heart rate, vascular tone, brain blood flow, blood glucose levels and the like.
- compounds which are considered to be "selective" for a particular melanocortin receptor are those compounds with a functional activity characterized by an ECso at least about 2-fold, at least about 5-fold, at least about 10- fold, at least about 15-fold, at least about 17-fold, ' at least about 90-fold, at least about 200-fold, at least about 3000-fold or at least about 10,000-fold, or even greater, selectivity for any melanocortin receptor as compared to any other melanocortin receptor.
- a selective melanocortin 4 receptor agonist of the invention exhibits a functional activity characterized by an ECso at least about 15-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 1 receptor, the human melanocortin 3 receptor and the human melanocortin 5 receptor.
- a selective melanocortin 4 receptor agonist of the invention exhibits a functional activity characterized by an ECso at least 17-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 3 receptor.
- the peptides of this invention can be prepared by standard solid phase peptide synthesis. See, e.g., Stewart, J.M., et al., Solid Phase Synthesis (Pierce Chemical Co., 2d ed. 1984).
- the substituents R 2 and R 3 of the above generic formula may be attached to the free amine of the N-terminal amino acid by standard methods known in the art.
- alkyl groups e.g., (Ci-C3o)alkyl, may be attached using reductive alkylation.
- Hydroxyalkyl groups e.g., (Q-C3o)hydroxyalkyl
- Acyl groups e.g., COE 1
- R 1 When R 1 is -NH2, the synthesis of the peptide starts with an Fmoc-amino acid which is coupled to the Rink Amide MBHA resin. If R 1 is -OH, the synthesis of the peptide starts with a Fmoc-amino acid which is coupled to Wang resin.
- the coupling time is 2 hours for these residues and the residue immediately following them.
- the title peptide was synthesized on an Advanced ChemTech model 396 ® multiple peptide synthesizer (Louisville, KY 40228) using Fluorenylmethyloxycarbonyl (Fmoc) chemistry.
- a Rink Amide 4- methylbenzylhydrylamine (MBHA) resin (Novabiochem ® , San Diego, CA) with substitution of 0.58 mmol/g was used.
- the Fmoc amino acids (Novabiochem ® , CA and Chem-Impex®, IL) used were Fmoc-Nle-OH, Fmoc-Cys(Trt)-OH, Fmoc-D-Ala- OH, Fmoc-His(Trt)-OH, Fmoc-D-Phe-OH, Fmoc-Arg(Pbf)-OH, and Fmoc-Trp(Boc)- OH.
- the synthesis was carried out on a 0.035 mmol scale.
- the Fmoc groups were removed by treatment with 25% piperidine in N, ⁇ [-dimethylformamide (DMF) for 30 minutes.
- the ACT 396 ® multiple peptide synthesizer was programmed to perform the following reaction cycle: (1) washing with DMF, (2) removing Fmoc protecting group with 25% piperidine in DMF for 30 minutes, (3) washing with DMF, (4) coupling with Fmoc amino acid in the presence of DIC and HOBT for 1 hour, (5) washing with DMF, (6) double-coupling with the same Fmoc amino acid in step 4 in the presence of HBTU, HOBt, and DIEA for 1 hour.
- the resin was coupled successively according to the sequence of the title peptide. After the peptide chain was assembled and the last Fmoc- protecting group was removed, the resin was washed completely by using DMF and dichloromethane (DCM).
- the resin was treated with a solution (1.5 mL) of TFA, H2O and triisopropylsilane (TIS) (v/v/v: 90/6.2/3.8) for 2 hours at room temperature.
- TFA triisopropylsilane
- the resin was filtered off and the filtrate was poured into 30 mL of ether.
- the precipitate was collected by centrifugation.
- This crude product was dissolved in water ( ⁇ 7 mL) and the pH of the aqueous solution was adjusted to ⁇ 7.5 by adding 2N NH4HCO3. The solution was opened to the air for 72 hours at room temperature.
- the resulting crude product was purified on a reverse-phase preparative HPLC system with a column (4 x 43 cm) of Ci ⁇ DYNAMAX-100 ® A 0 (Varian®, Walnut Creek, CA). The column was eluted over approximately 1 hour using a linear gradient of 85% A:15% B to 30% A:70% B, where A was 0.1% TFA in water and B was 0.1% TFA in acetonitrile. The fractions were checked by analytical HPLC and those containing pure product were pooled and lyophilized to dryness to give 10.3 mg (27% yield) of a white solid. Purity was assayed using HPLC and found to be approximately 88%. Electro-spray ionization mass spectrometry (ESI-MS) analysis gave the molecular weight at 1073.6 (in agreement with the calculated molecular weight of 1074.3).
- ESI-MS Electro-spray ionization mass spectrometry
- Boc amino acids (Novabiochem ® , San Diego, CA and Chem-Impex ® , Wood Dale, IL) used were: Boc- Cha-OH, Boc-Asp(OFm)-OH, Boc-His(DNP)-OH, Boc-D-Phe-OH, Boc-Arg(Tos)-OH, Boc-Trp(For)-OH, Boc-Gaba-OH, and Boc-Lys(Fmoc)-OH.
- the synthesis was carried out on a 0.20 mmol scale.
- the Boc groups were removed by treatment with 100% TFA for 2 x 1 minute.
- Boc amino acids (2.5 mmol) were pre-activated with HBTU (2.0 mmol) and DIEA (1.O mL) in 4 mL of DMF and were coupled without prior neutralization of the peptide-resin TFA salt. Coupling times were 5 minutes.
- the resin was treated twice with 25% piperidine in DMF for 15 minutes per session, washed with DMF, and shaken with bromo-tris-pyrrolidino- phosphonium hexafluorophosphate (PyBrOP) (6 eq, 0.3 mmol), DIEA (1 mL), and 4- (dimethylamino)pyridine (DMAP) (24 mg) in DMF (2 mL) for 12 hours. After washing with DMF, the resin was treated twice with 100% TFA for 2 minutes per treatment, washed with DMF and DCM, and then dried under reduced pressure.
- PrOP bromo-tris-pyrrolidino- phosphonium hexafluorophosphate
- DIEA dimethylamino)pyridine
- DMAP 4- (dimethylamino)pyridine
- One fourth of the peptide-resin (0.05 mmol) was used for the next coupling with Boc- Cha-OH (10 eq, 0.5 mmol) in the presence of HBTU (9 eq, 0.45 mmol) and DIEA (0.25 mL) in DMF for 10 minutes. After the deprotection with 100% TFA in two sessions lasting approximately 2 minutes each, the peptide-resin was then washed with DMF. The final capping step was done by shaking the resin with acetic anhydride (40 eq, 2.0 mmol) and DIEA (20 eq, 1.0 mmol) in DMF for 1 hour.
- the resin was treated twice with a solution of 20% mercaptoethanol/10% DIEA in DMF, each treatment lasting approximately 30 minutes, to remove the DNP group on the Histidine side chain.
- the formyl group on the side chain of Tryptophan was removed by shaking with a solution of 15% ethanolamine/ 15% water/ 70% DMF twice for 30 minutes per shaking.
- the peptide-resin was washed with DMF and DCM and dried under reduced pressure.
- the final cleavage was done by stirring the peptide-resin in 10 mL of HF containing 1 mL of anisole and dithiothreitol (30 mg) at O 0 C for 75 minutes.
- HF was removed by a flow of nitrogen.
- the residue was washed with ether (6 x 10 mL) and extracted with 4N HOAc (6 x 10 mL).
- the peptide mixture in the aqueous extract was purified on reverse-phase preparative high pressure liquid chromatography (HPLC) using a reverse phase VYD AC ® Ci8 column (Nest Group ® , Southborough, MA).
- HPLC reverse phase preparative high pressure liquid chromatography
- Fractions were collected and checked on analytical HPLC. Those containing pure product were combined and lyophilized to dryness. 5.1 mg of a white solid was obtained. Yield was 8.9%.
- Purity was 94.5% based on analytical HPLC analysis. Electro-spray mass spectrometer (MS(ES))S analysis gave the molecular weight at 1148.5 (in agreement with the calculated molecular weight of 1148.3).
- peptides of the invention can be prepared by a person of ordinary skill in the art using synthetic procedures analogous to those disclosed generally hereinabove and/or to those disclosed specifically in the foregoing examples, as were the compounds depicted in Tables IA and IB.
- peptides of the invention can be prepared by a person of ordinary skill in the art using synthetic procedures analogous to those disclosed generally hereinabove and/or to those disclosed specifically in the foregoing examples, as were the compounds depicted in Tables IA and IB.
- peptides of the invention can be prepared by a person of ordinary skill in the art using synthetic procedures analogous to those disclosed generally hereinabove and/or to those disclosed specifically in the foregoing examples, as were the compounds depicted in Tables IA and IB.
- Cellular membranes used for the in vitro receptor binding assays were obtained from transgenic CHO-Kl cells stably expressing hMC-R receptor subtypes 1, 3, 4 or 5.
- the CHO-Kl cells expressing the desired hMC-R receptor type were sonicated (Branson ® setting 7, approximately 30 sec) in ice-cold 50 mM Tris-HCl at pH 7.4 and then centrifuged at 39,000 g for 10 minutes at approximately 4°C.
- the pellets were resuspended in the same buffer and centrifuged at 50,000 g for 10 minutes at approximately 4°C.
- the washed pellets containing the cellular membranes were stored at approximately - 80 0 C.
- Bound [ 125 I]-NDP-Ct-MSH ligand was separated from free [ 125 I]- NDP- ⁇ -MSH by filtration through GF/C glass fiber filter plates (Unifilter ® ; Packard) presoaked with 0.1 % (w/v) polyethylenimine (PEI), using a Packard Filtermate ® harvester. Filters were washed three times with 50 mM Tris-HCl at pH 7.4 at a temperature of approximately 0-4 0 C and then assayed for radioactivity using a Packard Topcount ® scintillation counter. Binding data were analyzed by computer- assisted non-linear regression analysis (XL fit; IDBS).
- Intracellular cyclic AMP (cAMP) levels were determined by an electrochemiluminescence (ECL) assay (Meso Scale Discovery ® , Gaithersburg, MD; referred to hereinafter as MSD).
- ECL electrochemiluminescence
- CHO-Kl cells stably expressing the hMC receptor subtypes were suspended in RMPI 1640 ® assay buffer (RMPI 1640 buffer contains 0.5 mM isobutylmethylxanthine (IBMX), and 0.2% protein cocktail (MSD blocker A)).
- Transgenic CHO-Kl cells stably expressing hMC receptor subtypes 1, 3, 4 or 5 were dispensed at a density of approximately 7,000 cells/well in 384-well Multi-Array ® plates (MSD) containing integrated carbon electrodes and coated with anti-cAMP antibody. Increasing concentrations of the test compounds were added and the cells were incubated for approximately 40 minutes at approximately 37°C. Following this incubation, lysis buffer (HEPES-buffered saline solution with MgCh and Triton X- 100® at ph 7.3) containing 0.2% protein cocktail and 2.5 nM TAGTM ruthenium- labeled cAMP (MSD) was added and the cells were incubated for approximately 90 minutes at room temperature.
- lysis buffer HPES-buffered saline solution with MgCh and Triton X- 100® at ph 7.3
- read buffer Tris-buffered solution containing an ECL co-reactant and Triton X-100 at ph 7.8
- MSD Sector Imager 6000 reader ®
- ECso represents the concentration of an agonist compound needed to obtain 50% of the maximum reaction response, e.g., 50% of the maximum level of cAMP as determined using the assay described above.
- the Kb value reflects the potency of an antagonist and is determined by Schild analysis. In brief, concentration-response curves of an agonist are carried out in the presence of increasing concentrations of an antagonist. The Kb value is the concentration of antagonist which would produce a 2-fold shift in the concentration-response curve for an agonist. It is calculated by extrapolating the line on a Schild plot to zero on the y-axis.
- Compounds of the present invention can be and were tested for an effect upon food intake and/or body weight according to the following procedures.
- One skilled in the art would know that procedures similar to those described herein may be used to assay the effect of the compounds of the invention upon food intake and/or body weight.
- mice Male Sprague Dawley rats (25Og) were housed in individual cages and maintained under 12:12 hour light:dark conditions. The rats were fasted for 18 hours prior to the start of the experiment with water available ad libitum. At time 0, the rats were injected subcutaneously (sc) with selected compounds at doses of either 500 or 100 nmole/kg, or with vehicle, and were provided with food. Individual food consumption was measured at about 1, 2, 3, 4, 5 and 6 hours after injection. Data for selected compounds of the invention are reported in Figures IA and IB.
- Acute feeding experiments Male Sprague Dawley rats (25Og) are housed in individual cages and maintained under 12:12 hour lightdark conditions. Food and water is available ad libitum throughout the experiment. At time 0, the rats are injected sc with compound at doses of either 500 or 100 nmole/kg, or with vehicle. Individual food consumption is measured at about 1, 2, 3, 4, 5 and 6 hours after injection.
- mice Male Sprague Dawley rats (25Og) were housed in individual cages and maintained under 12:12 hour lightdark conditions with both food and water available ad libitum. The rats were injected sc 3x/day (approximately 0800 hour, 1200 hour, and 1600 hour) with compound at various doses or with vehicle for 7 days. Individual body weight and food consumption were measured daily. Data for selected compounds of the invention are reported in Figures 2A and IB, Figures 3A and 3B, and Figures 4A and 4B.
- the peptides of this invention can be provided in the form of pharmaceutically acceptable salts.
- such salts include, but are not limited to, those formed with organic acids (e.g., acetic, lactic, maleic, citric, malic, ascorbic, succinic, benzoic, methanesulfonic, toluenesulfonic, or pamoic acid), inorganic acids (e.g., hydrochloric acid, sulfuric acid, or phosphoric add), and polymeric acids (e.g., tannic acid, carboxymethyl cellulose, polylactic, polyglycolic, or copolymers of polylactic-glycolic acids).
- organic acids e.g., acetic, lactic, maleic, citric, malic, ascorbic, succinic, benzoic, methanesulfonic, toluenesulfonic, or pamoic acid
- inorganic acids e.g., hydrochloric acid, sulfuric acid, or
- a typical method of making a salt of a peptide of the present invention is well known in the art and can be accomplished by standard methods of salt exchange. Accordingly, the TFA salt of a peptide of the present invention (the TFA salt results from the purification of the peptide by using preparative HPLC, eluting with TFA containing buffer solutions) can be converted into another salt, such as an acetate salt, by dissolving the peptide in a small amount of 0.25 N acetic acid aqueous solution. The resulting solution is applied to a semi- prep HPLC column (Zorbax ® , 300 SB, C-8).
- the column is eluted with: (1) 0.1N ammonium acetate aqueous solution for 0.5 hours; (2) 0.25N acetic acid aqueous .olution for 0.5 hours; and (3) a linear gradient (20% to 100% of solution B over 30 ninutes) at a flow rate of 4 ml/min (solution A is 0.25N acetic acid aqueous solution; iolution B is 0.25N acetic acid in acetonitrile/water, 80:20).
- solution A is 0.25N acetic acid aqueous solution
- iolution B is 0.25N acetic acid in acetonitrile/water, 80:20.
- the fractions containing he peptide are collected and lyophilized to dryness.
- M-R Deptides with melanocortin receptor
- compositions comprising, as an active ingredient, at least one of the compounds of formula (I) in association with a pharmaceutically acceptable carrier.
- the dosage of active ingredient in the compositions of this invention may be varied; however, it is necessary that the amount of the active ingredient be such that a suitable dosage form is obtained.
- the selected dosage depends upon the desired therapeutic effect, on the route of administration, and on the duration of the treatment.
- an effective dosage for the activities of this invention is in the range of IxIO" 7 to 200 mg/kg/day, preferably IxIO 4 to 100 mg/kg/day which can be administered as a single dose or divided into multiple doses.
- the compounds of this invention can be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous or subcutaneous injection, or implant), nasal, vaginal, rectal, sublingual or topical routes of administration and can be formulated with pharmaceutically acceptable carriers to provide dosage forms appropriate for each route of administration.
- parenteral e.g., intramuscular, intraperitoneal, intravenous or subcutaneous injection, or implant
- nasal, vaginal, rectal, sublingual or topical routes of administration can be formulated with pharmaceutically acceptable carriers to provide dosage forms appropriate for each route of administration.
- Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules.
- the active compound is admixed with at least one inert pharmaceutically acceptable carrier such as sucrose, lactose, or starch.
- Such dosage forms can also comprise, as is normal practice, additional substances other than such inert diluents, e.g., lubricating agents such as magnesium stearate.
- the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.
- Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, the elixirs containing inert diluents commonly used in the art, such as water. Besides such inert diluents, compositions can also include adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring and perfuming agents.
- Preparations according to this invention for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, or emulsions.
- non-aqueous solvents or vehicles are propylene glycol, polyethylene glycol, vegetable oils, such as olive oil and corn oil, gelatin, and injectable organic esters such as ethyl oleate.
- Such dosage forms may also contain adjuvants such as preserving, wetting, emulsifying, and dispersing agents.
- Preparations may be sterilized by, for example, filtration through a bacteria-retaining filter, by incorporating sterilizing agents into the compositions, by irradiating the compositions, or by heating the compositions.
- Preparations can also be manufactured in the form of sterile solid compositions which can be dissolved in sterile water or some other sterile injectable medium immediately before use.
- compositions for rectal or vaginal administration are preferably suppositories which may contain, in addition to the active substance, exdpients such as cocoa butter or a suppository wax.
- compositions for nasal or sublingual administration are also prepared with standard excipients well known in the art.
- a compound of this invention can be administered in a sustained release composition such as those described in the following patents and patent applications.
- U.S. Patent No. 5,672,659 teaches sustained release compositions comprising a bioactive agent and a polyester.
- U.S. Patent No. 5,595,760 teaches sustained release compositions comprising a bioactive agent in a gelable form.
- U.S. Patent No. 5,821,221 teaches polymeric sustained release compositions comprising a bioactive agent and chitosan.
- U.S. Patent No. 5,916,883 teaches sustained release compositions comprising a bioactive agent and cyclodextrin. The teachings of the foregoing patents and applications are incorporated herein by reference.
Abstract
Description
Claims
Priority Applications (21)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2614615A CA2614615C (en) | 2005-07-08 | 2006-07-10 | Melanocortin receptor ligands |
KR1020097022845A KR101232201B1 (en) | 2005-07-08 | 2006-07-10 | Melanocortin receptor ligands |
NZ565217A NZ565217A (en) | 2005-07-08 | 2006-07-10 | Melanocortin receptor ligands |
AU2006269261A AU2006269261B2 (en) | 2005-07-08 | 2006-07-10 | Melanocortin receptor ligands |
EP06786665A EP1915167A4 (en) | 2005-07-08 | 2006-07-10 | Melanocortin receptor ligands |
US11/988,533 US8039435B2 (en) | 2005-07-08 | 2006-07-10 | Melanocortin receptor ligands |
JP2008520417A JP4734411B2 (en) | 2005-07-08 | 2006-07-10 | Melanocortin receptor ligand |
EP17202836.7A EP3354273B1 (en) | 2005-07-08 | 2006-07-10 | Melanocortin receptor ligands |
PL17202836T PL3354273T3 (en) | 2005-07-08 | 2006-07-10 | Melanocortin receptor ligands |
CN2006800324235A CN101257916B (en) | 2005-07-08 | 2006-07-10 | Melanocortin receptor ligands |
EP21163411.8A EP3925614A3 (en) | 2005-07-08 | 2006-07-10 | Melanocortin receptor ligands |
IL188545A IL188545A (en) | 2005-07-08 | 2008-01-02 | Melanocortin receptor agonist compound, pharmaceutical composition comprising such a compound and use thereof in the manufacture of medicaments for treating disorders |
IL201732A IL201732A (en) | 2005-07-08 | 2009-10-25 | Melanocortin receptor ligands |
US13/074,565 US9458195B2 (en) | 2005-07-08 | 2011-03-29 | Melanocortin receptor ligands |
IL246392A IL246392A (en) | 2005-07-08 | 2016-06-22 | Melanocortin receptor ligands |
US15/257,970 US20160368962A1 (en) | 2005-07-08 | 2016-09-07 | Melanocortin Receptor Ligands |
US15/587,426 US9850280B2 (en) | 2005-07-08 | 2017-05-05 | Melanocortin receptor ligands |
US15/830,038 US20180105557A1 (en) | 2005-07-08 | 2017-12-04 | Melanocortin Receptor Ligands |
US16/029,837 US20180305406A1 (en) | 2005-07-08 | 2018-07-09 | Melanocortin Receptor Ligands |
US16/702,661 US20200095281A1 (en) | 2005-07-08 | 2019-12-04 | Melanocortin Receptor Ligands |
US17/572,115 US20220127305A1 (en) | 2005-07-08 | 2022-01-10 | Melanocortin receptor ligands |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69777905P | 2005-07-08 | 2005-07-08 | |
US60/697,779 | 2005-07-08 | ||
US74885005P | 2005-12-09 | 2005-12-09 | |
US60/748,850 | 2005-12-09 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/988,533 A-371-Of-International US8039435B2 (en) | 2005-07-08 | 2006-07-10 | Melanocortin receptor ligands |
US13/074,565 Continuation US9458195B2 (en) | 2005-07-08 | 2011-03-29 | Melanocortin receptor ligands |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007008704A2 true WO2007008704A2 (en) | 2007-01-18 |
WO2007008704A3 WO2007008704A3 (en) | 2007-10-11 |
Family
ID=37637790
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/026586 WO2007008704A2 (en) | 2005-07-08 | 2006-07-10 | Melanocortin receptor ligands |
Country Status (21)
Country | Link |
---|---|
US (8) | US8039435B2 (en) |
EP (6) | EP2236151B1 (en) |
JP (4) | JP4734411B2 (en) |
KR (2) | KR100997177B1 (en) |
CN (4) | CN101676298A (en) |
AU (2) | AU2006269261B2 (en) |
CA (4) | CA3228910A1 (en) |
DK (4) | DK3354273T3 (en) |
ES (4) | ES2386862T3 (en) |
FR (1) | FR21C1060I2 (en) |
HK (2) | HK1149190A1 (en) |
HU (4) | HUE055154T2 (en) |
IL (3) | IL188545A (en) |
NL (1) | NL301150I2 (en) |
NZ (2) | NZ565217A (en) |
PL (4) | PL2286825T3 (en) |
PT (4) | PT2286825T (en) |
RU (2) | RU2380372C2 (en) |
SG (1) | SG163585A1 (en) |
SI (1) | SI3354273T1 (en) |
WO (1) | WO2007008704A2 (en) |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102007020152A1 (en) * | 2007-04-26 | 2008-10-30 | Charité - Universitätsmedizin Berlin | Agent for anti-infective treatment of a patient |
WO2008156677A3 (en) * | 2007-06-15 | 2009-04-16 | Sod Conseils Rech Applic | Cyclic peptide melanocortin receptor ligands |
WO2008147556A3 (en) * | 2007-05-25 | 2009-12-23 | Ipsen Pharma S.A.S. | Melanocortin receptor ligands modified with hydantoin |
EP2214693A2 (en) * | 2007-11-05 | 2010-08-11 | Ipsen Pharma S.A.S. | Use of melanocortins to treat insulin sensitivity |
WO2011017209A1 (en) * | 2009-08-05 | 2011-02-10 | Ipsen Pharma S.A.S. | Use of melanocortins to treat dyslipidemia |
WO2011060352A1 (en) * | 2009-11-16 | 2011-05-19 | Ipsen Pharma S.A.S. | Pharmaceutical compositions of melanocortin receptor ligands |
WO2011060355A1 (en) * | 2009-11-16 | 2011-05-19 | Ipsen Pharma S.A.S | Process for the synthesis of ac-arg-cyclo(cys-d-ala-his-d-phe-arg-trp-cys)-nh2 |
WO2011026015A3 (en) * | 2009-08-31 | 2011-07-21 | Gruber Kenneth A | Stabilized melanocortin ligands |
WO2012172433A2 (en) | 2011-06-14 | 2012-12-20 | Ipsen Pharma S.A.S. | A sustained-release composition containing peptides as active ingredient |
US8440793B2 (en) | 2008-05-27 | 2013-05-14 | Genzyme Corporation | Peptide analogs of alpha-melanocyte stimulating hormone |
WO2013102047A1 (en) | 2011-12-29 | 2013-07-04 | Rhythm Pharmaceuticals, Inc. | Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers |
US8487073B2 (en) | 2008-06-09 | 2013-07-16 | Palatin Technologies, Inc. | Melanocortin receptor-specific peptides for treatment of sexual dysfunction |
EP2705835A1 (en) | 2012-06-08 | 2014-03-12 | Ipsen Pharma S.A.S. | Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release |
WO2014144260A1 (en) * | 2013-03-15 | 2014-09-18 | Rhythm Metabolic, Inc. | Peptide compositions |
US8846601B2 (en) | 2009-06-08 | 2014-09-30 | Palatin Technologies, Inc. | Melanocortin receptor-specific peptides |
US8933194B2 (en) | 2009-11-23 | 2015-01-13 | Palatin Technologies, Inc. | Melanocortin-1 receptor-specific linear peptides |
WO2014144842A3 (en) * | 2013-03-15 | 2015-04-09 | Rhythm Metabolic, Inc. | Pharmaceutical compositions |
US9040663B2 (en) | 2009-06-08 | 2015-05-26 | Astrazeneca Ab | Melanocortin receptor-specific peptides |
US9273098B2 (en) | 2009-06-08 | 2016-03-01 | Palatin Technologies, Inc. | Lactam-bridged melanocortin receptor-specific peptides |
US9951116B2 (en) | 2012-10-19 | 2018-04-24 | Txp Pharma Gmbh | Alpha- and gamma-MSH analogues |
US10017539B2 (en) | 2009-11-23 | 2018-07-10 | Palatin Technologies, Inc. | Melanocortin-1 receptor-specific cyclic hexapeptides |
WO2018167194A1 (en) * | 2017-03-15 | 2018-09-20 | Novo Nordisk A/S | Bicyclic compounds capable of binding to melanocortin 4 receptor |
WO2019195756A1 (en) | 2018-04-06 | 2019-10-10 | Rhythm Pharmaceuticals, Inc. | Compositions for treating kidney disease |
WO2019219714A1 (en) * | 2018-05-15 | 2019-11-21 | Novo Nordisk A/S | Compounds capable of binding to melanocortin 4 receptor |
US10960046B2 (en) | 2015-09-30 | 2021-03-30 | Rhythm Pharmaceuticals, Inc. | Method of treating melanocortin-4 receptor pathway-associated disorders |
US11141455B2 (en) | 2014-04-22 | 2021-10-12 | Txp Pharma Gmbh | Peptide analogues with branched amino acid probe(s) |
WO2022067086A1 (en) * | 2020-09-24 | 2022-03-31 | Rhythm Pharmaceuticals, Inc. | Methods of treating melanocortin-4 receptor pathway-associated disorders |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10232018B2 (en) | 2013-03-14 | 2019-03-19 | Mallinckrodt Ard Ip Limited | ACTH for treatment of acute respiratory distress syndrome |
US10653743B2 (en) * | 2015-10-15 | 2020-05-19 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods for the treatment of depression and anxiety by a melanocortin 5 receptor antagonist, PG-20N |
WO2018074999A1 (en) * | 2016-10-17 | 2018-04-26 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Novel modulators of melanocortin receptors for the treatment of depression and anxiety |
US11542302B2 (en) | 2015-10-15 | 2023-01-03 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Modulators of melanocortin receptors for the treatment of depression and anxiety |
US11396535B2 (en) | 2019-03-01 | 2022-07-26 | Provincial Health Services Authority | Cyclic peptide analogs of melanocortin and amanitin and methods of making such |
EP4347019A1 (en) * | 2021-05-27 | 2024-04-10 | The Regents Of The University Of Michigan | Mc3r agonist peptides |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US613874A (en) | 1898-11-08 | George e | ||
US1613874A (en) | 1922-03-29 | 1927-01-11 | Miner Inc W H | Friction draft gear |
US5652214A (en) | 1989-06-05 | 1997-07-29 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factors and analogs |
US5672659A (en) | 1993-01-06 | 1997-09-30 | Kinerton Limited | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
US5595760A (en) | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
US5665702A (en) | 1995-06-06 | 1997-09-09 | Biomeasure Incorporated | Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides |
US5916883A (en) | 1996-11-01 | 1999-06-29 | Poly-Med, Inc. | Acylated cyclodextrin derivatives |
SE9700620D0 (en) | 1997-02-21 | 1997-02-21 | Wapharm Ab | Cyclic peptides with selectivity for MSH receptor subtypes |
US6350430B1 (en) | 1997-10-27 | 2002-02-26 | Lion Bioscience Science Ag | Melanocortin receptor ligands and methods of using same |
WO1999055679A1 (en) * | 1998-04-28 | 1999-11-04 | Trega Biosciences, Inc. | Isoquinoline compound melanocortin receptor ligands and methods of using same |
PL346223A1 (en) * | 1998-07-27 | 2002-01-28 | Univ Iowa State Res Found Inc | Melanocortin-4 receptor gene and use as a genetic marker for fat content, weight gain, and/or feed consumption of animals |
WO2000010507A2 (en) | 1998-08-21 | 2000-03-02 | The Children's Medical Center Corporation | Use of melanin for inhibition of angiogenesis and macular degeneration |
US6716810B1 (en) | 1998-12-09 | 2004-04-06 | Eleanor Roosevelt Institute | Composition and method for regulation of body weight and associated conditions |
US6603058B1 (en) | 1998-12-09 | 2003-08-05 | Oklahoma Medical Research Foundation | Non-human animal model for obesity and uses thereof |
KR100558131B1 (en) | 1999-03-29 | 2006-03-10 | 더 프록터 앤드 갬블 캄파니 | A pharmaceutical composition comprising melanocortin receptor ligands and a manufacture of a medicament comprising melanocornin receptor ligands |
US6579968B1 (en) * | 1999-06-29 | 2003-06-17 | Palatin Technologies, Inc. | Compositions and methods for treatment of sexual dysfunction |
US7176279B2 (en) | 2000-06-28 | 2007-02-13 | Palatin Technologies, Inc. | Cyclic peptide compositions and methods for treatment of sexual dysfunction |
WO2001033954A1 (en) | 1999-11-12 | 2001-05-17 | Merck & Co., Inc. | Melanocortin-3 receptor deficient cells, non-human transgenic animals and methods of selecting compounds which regulate body weight |
US6600015B2 (en) | 2000-04-04 | 2003-07-29 | Hoffmann-La Roche Inc. | Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity |
PL360855A1 (en) * | 2000-06-28 | 2004-09-20 | Pfizer Products Inc. | Melanocortin receptor ligands |
US6720324B2 (en) | 2000-07-05 | 2004-04-13 | Synaptic Pharmaceutical Corporation | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof |
CA2422068A1 (en) | 2000-09-13 | 2002-03-21 | Eleanor Roosevelt Institute | Method for treatment of insulin resistance in obesity and diabetes |
US20030113263A1 (en) | 2001-02-13 | 2003-06-19 | Oregon Health And Sciences University, A Non-Profit Organization | Methods and reagents for using mammalian melanocortin receptor antagonists to treat cachexia |
JP2004532838A (en) | 2001-03-02 | 2004-10-28 | ブリストル−マイヤーズ スクイブ カンパニー | Compounds useful as melanocortin receptor modulators and pharmaceutical compositions containing them |
US6770645B2 (en) * | 2001-03-16 | 2004-08-03 | Pfizer Inc. | Pharmaceutically active compounds |
JP2004534851A (en) * | 2001-07-11 | 2004-11-18 | パラチン テクノロジーズ インク. | Linear and cyclic peptides specific for the melanocortin receptor |
US7034004B2 (en) | 2002-05-07 | 2006-04-25 | University Of Florida | Peptides and methods for the control of obesity |
US20040128136A1 (en) * | 2002-09-20 | 2004-07-01 | Irani Pourang Polad | Internet voice browser |
AU2004251616A1 (en) * | 2003-06-19 | 2005-01-06 | Eli Lilly And Company | Melanocortin receptor 4(MC4) agonists and their uses |
WO2005000338A1 (en) * | 2003-06-19 | 2005-01-06 | Eli Lilly And Company | Uses of melanocortin-3 receptor (mc3r) agonist peptides |
US7084111B2 (en) | 2003-06-23 | 2006-08-01 | University Of Florida Research Foundation, Inc. | Melanocortin receptor templates, peptides, and use thereof |
CA2532026C (en) | 2003-08-20 | 2012-04-17 | Eli Lilly And Company | Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide |
US20070293423A1 (en) | 2003-08-20 | 2007-12-20 | Eli Lilly And Company | Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide |
US20050192286A1 (en) * | 2003-10-22 | 2005-09-01 | Neurocrine Biosciences, Inc. | Ligands of melanocortin receptors and compositions and methods related thereto |
DE10355559A1 (en) | 2003-11-21 | 2005-06-23 | Orthogen Ag | Transskin |
WO2005060985A1 (en) | 2003-12-10 | 2005-07-07 | Merck & Co., Inc. | Inhibition of voluntary ethanol consumption with selective melanocortin 4-receptor agonists |
CA2557739A1 (en) | 2004-03-29 | 2005-11-03 | Eli Lilly And Company | Uses of melanocortin-4 receptor (mc4r) agonist peptides administered by continuous infusion |
AU2005291862B2 (en) | 2004-10-08 | 2010-07-08 | Clinuvel Pharmaceuticals Limited | Compositions and methods for inducing melanogenesis in a subject |
WO2006073771A2 (en) | 2005-01-05 | 2006-07-13 | Eli Lilly And Company | Polyethylene glycol linked mc4r or mc3r agonist peptides |
WO2006073772A1 (en) | 2005-01-05 | 2006-07-13 | Eli Lilly And Company | Polyethylene glycol linked mc4r or mc3r agonist peptides |
DK1919947T3 (en) | 2005-08-26 | 2013-03-18 | Abbvie Inc | Therapeutically active alpha-MSH analogs |
-
2006
- 2006-07-10 CA CA3228910A patent/CA3228910A1/en active Pending
- 2006-07-10 PT PT101825669T patent/PT2286825T/en unknown
- 2006-07-10 PT PT121887848T patent/PT2548568T/en unknown
- 2006-07-10 CA CA2793119A patent/CA2793119C/en active Active
- 2006-07-10 DK DK17202836.7T patent/DK3354273T3/en active
- 2006-07-10 RU RU2008104803/04A patent/RU2380372C2/en active
- 2006-07-10 KR KR1020087002955A patent/KR100997177B1/en active IP Right Grant
- 2006-07-10 ES ES10170694T patent/ES2386862T3/en active Active
- 2006-07-10 PT PT10170694T patent/PT2236151E/en unknown
- 2006-07-10 EP EP10170694A patent/EP2236151B1/en active Active
- 2006-07-10 PT PT172028367T patent/PT3354273T/en unknown
- 2006-07-10 WO PCT/US2006/026586 patent/WO2007008704A2/en active Application Filing
- 2006-07-10 CN CN200910174061A patent/CN101676298A/en active Pending
- 2006-07-10 DK DK12188784.8T patent/DK2548568T3/en active
- 2006-07-10 SI SI200632406T patent/SI3354273T1/en unknown
- 2006-07-10 CA CA3044795A patent/CA3044795A1/en not_active Abandoned
- 2006-07-10 NZ NZ565217A patent/NZ565217A/en unknown
- 2006-07-10 SG SG201004921-1A patent/SG163585A1/en unknown
- 2006-07-10 DK DK10182566.9T patent/DK2286825T3/en active
- 2006-07-10 ES ES12188784.8T patent/ES2663916T3/en active Active
- 2006-07-10 EP EP21163411.8A patent/EP3925614A3/en active Pending
- 2006-07-10 JP JP2008520417A patent/JP4734411B2/en active Active
- 2006-07-10 KR KR1020097022845A patent/KR101232201B1/en active IP Right Grant
- 2006-07-10 DK DK10170694.3T patent/DK2236151T3/en active
- 2006-07-10 PL PL10182566T patent/PL2286825T3/en unknown
- 2006-07-10 HU HUE17202836A patent/HUE055154T2/en unknown
- 2006-07-10 CN CN2006800324235A patent/CN101257916B/en active Active
- 2006-07-10 PL PL12188784T patent/PL2548568T3/en unknown
- 2006-07-10 AU AU2006269261A patent/AU2006269261B2/en active Active
- 2006-07-10 ES ES10182566.9T patent/ES2604328T3/en active Active
- 2006-07-10 PL PL10170694T patent/PL2236151T3/en unknown
- 2006-07-10 PL PL17202836T patent/PL3354273T3/en unknown
- 2006-07-10 ES ES17202836T patent/ES2877349T3/en active Active
- 2006-07-10 US US11/988,533 patent/US8039435B2/en active Active
- 2006-07-10 EP EP10182566.9A patent/EP2286825B1/en active Active
- 2006-07-10 RU RU2009131092/04A patent/RU2439079C2/en active
- 2006-07-10 NZ NZ580806A patent/NZ580806A/en not_active Application Discontinuation
- 2006-07-10 CN CN201610168908.2A patent/CN105837661A/en active Pending
- 2006-07-10 CA CA2614615A patent/CA2614615C/en active Active
- 2006-07-10 EP EP06786665A patent/EP1915167A4/en not_active Withdrawn
- 2006-07-10 EP EP12188784.8A patent/EP2548568B1/en active Active
- 2006-07-10 EP EP17202836.7A patent/EP3354273B1/en active Active
- 2006-07-10 HU HUE10182566A patent/HUE031731T2/en unknown
- 2006-07-10 CN CN201310495024.4A patent/CN103755786B/en active Active
- 2006-07-10 HU HUE12188784A patent/HUE037147T2/en unknown
-
2008
- 2008-01-02 IL IL188545A patent/IL188545A/en active IP Right Grant
- 2008-09-18 HK HK11103282.8A patent/HK1149190A1/en unknown
-
2009
- 2009-10-25 IL IL201732A patent/IL201732A/en active IP Right Grant
- 2009-10-28 AU AU2009230799A patent/AU2009230799B2/en active Active
- 2009-11-19 JP JP2009263603A patent/JP5889513B2/en active Active
-
2011
- 2011-03-29 US US13/074,565 patent/US9458195B2/en active Active
-
2013
- 2013-08-08 JP JP2013165312A patent/JP2013253090A/en active Pending
-
2015
- 2015-07-14 JP JP2015140154A patent/JP5965520B2/en active Active
-
2016
- 2016-06-22 IL IL246392A patent/IL246392A/en active IP Right Grant
- 2016-09-07 US US15/257,970 patent/US20160368962A1/en not_active Abandoned
-
2017
- 2017-05-05 US US15/587,426 patent/US9850280B2/en active Active
- 2017-12-04 US US15/830,038 patent/US20180105557A1/en not_active Abandoned
-
2018
- 2018-07-09 US US16/029,837 patent/US20180305406A1/en not_active Abandoned
-
2019
- 2019-01-28 HK HK19101447.6A patent/HK1258965A1/en unknown
- 2019-12-04 US US16/702,661 patent/US20200095281A1/en not_active Abandoned
-
2021
- 2021-12-06 NL NL301150C patent/NL301150I2/en unknown
- 2021-12-14 FR FR21C1060C patent/FR21C1060I2/en active Active
- 2021-12-15 HU HUS2100054C patent/HUS2100054I1/en unknown
-
2022
- 2022-01-10 US US17/572,115 patent/US20220127305A1/en active Pending
Non-Patent Citations (1)
Title |
---|
See references of EP1915167A4 * |
Cited By (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102007020152A1 (en) * | 2007-04-26 | 2008-10-30 | Charité - Universitätsmedizin Berlin | Agent for anti-infective treatment of a patient |
US9758549B2 (en) | 2007-05-25 | 2017-09-12 | Ipsen Pharma S.A.S. | Melanocortin receptor ligands modified with hydantoin |
US8563000B2 (en) | 2007-05-25 | 2013-10-22 | Ipsen Pharma S.A.S. | Melanocortin receptor ligands modified with hydantoin |
WO2008147556A3 (en) * | 2007-05-25 | 2009-12-23 | Ipsen Pharma S.A.S. | Melanocortin receptor ligands modified with hydantoin |
US9296783B2 (en) | 2007-05-25 | 2016-03-29 | Ipsen Pharma S.A.S. | Melanocortin receptor ligands modified with hydantoin |
JP2010528018A (en) * | 2007-05-25 | 2010-08-19 | イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ | Melanocortin receptor ligand modified with hydantoin |
EP2167112A4 (en) * | 2007-06-15 | 2012-01-25 | Ipsen Pharma Sas | Cyclic peptide melanocortin receptor ligands |
EP2167112A2 (en) * | 2007-06-15 | 2010-03-31 | Ipsen Pharma S.A.S. | Cyclic peptide melanocortin receptor ligands |
WO2008156677A3 (en) * | 2007-06-15 | 2009-04-16 | Sod Conseils Rech Applic | Cyclic peptide melanocortin receptor ligands |
EP2214693A2 (en) * | 2007-11-05 | 2010-08-11 | Ipsen Pharma S.A.S. | Use of melanocortins to treat insulin sensitivity |
EP2979703A1 (en) | 2007-11-05 | 2016-02-03 | Ipsen Pharma S.A.S. | Use of melanocortins to treat insulin sensitivity |
US9439943B2 (en) | 2007-11-05 | 2016-09-13 | Ipsen Pharma S.A.S. | Use of melanocortins to treat insulin sensitivity |
CN103316345A (en) * | 2007-11-05 | 2013-09-25 | 益普生制药股份有限公司 | Use melanocortins to treat insulin sensitivity |
EP2214693A4 (en) * | 2007-11-05 | 2012-04-11 | Ipsen Pharma Sas | Use of melanocortins to treat insulin sensitivity |
CN103316345B (en) * | 2007-11-05 | 2016-05-18 | 益普生制药股份有限公司 | The application of melanocortin treatment insulin sensitivity |
US9827286B2 (en) | 2007-11-05 | 2017-11-28 | Ipsen Pharma S.A.S. | Use of melanocortins to treat insulin sensitivity |
KR101662044B1 (en) * | 2007-11-05 | 2016-10-04 | 입센 파마 에스.에이.에스. | Use melanocortins to treat insulin sensitivity |
US9155777B2 (en) | 2007-11-05 | 2015-10-13 | Ipsen Pharma S.A.S. | Use of melanocortins to treat insulin sensitivity |
JP2011502987A (en) * | 2007-11-05 | 2011-01-27 | イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ | Use of melanocortins to treat insulin hypersensitivity |
KR20130065725A (en) * | 2007-11-05 | 2013-06-19 | 입센 파마 에스.에이.에스 | Use melanocortins to treat insulin sensitivity |
JP2015131827A (en) * | 2007-11-05 | 2015-07-23 | イプセン ファルマ ソシエテ パール アクシオン サンプリフィエIpsen Pharma S.A.S. | Use of melanocortins to treat insulin sensitivity |
CN101980717A (en) * | 2007-11-05 | 2011-02-23 | 益普生制药股份有限公司 | Use melanocortins to treat insulin sensitivity |
JP2013144690A (en) * | 2007-11-05 | 2013-07-25 | Ipsen Pharma Sas | Use of melanocortins to treat insulin sensitivity |
KR101290623B1 (en) * | 2007-11-05 | 2013-08-07 | 보드 오브 슈퍼바이저스 오브 루이지애나 스테이트 유니버시티 앤드 애그리컬추얼 앤드 메카니컬 컬리지 | Use of melanocortins to treat insulin sensitivity |
US8440793B2 (en) | 2008-05-27 | 2013-05-14 | Genzyme Corporation | Peptide analogs of alpha-melanocyte stimulating hormone |
US10385108B2 (en) | 2008-05-27 | 2019-08-20 | Genzyme Corporation | Peptide analogs of alpha-melanocyte stimulating hormone |
US9115174B2 (en) | 2008-05-27 | 2015-08-25 | Genzyme Corporation | Peptide analogs of alpha-melanocyte stimulating hormone |
US9738698B2 (en) | 2008-05-27 | 2017-08-22 | Genzyme Corporation | Peptide analogs of alpha-melanocyte stimulating hormone |
US8487073B2 (en) | 2008-06-09 | 2013-07-16 | Palatin Technologies, Inc. | Melanocortin receptor-specific peptides for treatment of sexual dysfunction |
US8729224B2 (en) | 2008-06-09 | 2014-05-20 | Palatin Technologies, Inc. | Melanocortin receptor-specific peptides for treatment of female sexual dysfunction |
US10632171B2 (en) | 2009-06-08 | 2020-04-28 | Palatin Technologies, Inc. | Melanocortin receptor-specific peptides |
US8846601B2 (en) | 2009-06-08 | 2014-09-30 | Palatin Technologies, Inc. | Melanocortin receptor-specific peptides |
US9040663B2 (en) | 2009-06-08 | 2015-05-26 | Astrazeneca Ab | Melanocortin receptor-specific peptides |
US10179804B2 (en) | 2009-06-08 | 2019-01-15 | Palatin Technologies, Inc. | Melanocortin receptor-specific peptides |
US9458201B2 (en) | 2009-06-08 | 2016-10-04 | Palatin Technologies, Inc. | Melanocortin receptor-specific heptapeptides |
US9273098B2 (en) | 2009-06-08 | 2016-03-01 | Palatin Technologies, Inc. | Lactam-bridged melanocortin receptor-specific peptides |
WO2011017209A1 (en) * | 2009-08-05 | 2011-02-10 | Ipsen Pharma S.A.S. | Use of melanocortins to treat dyslipidemia |
US20120135923A1 (en) * | 2009-08-05 | 2012-05-31 | Ipsen Pharma, S.A.S. | Use of Melanocortins to Treat Dyslipidemia |
WO2011026015A3 (en) * | 2009-08-31 | 2011-07-21 | Gruber Kenneth A | Stabilized melanocortin ligands |
CN102686601A (en) * | 2009-11-16 | 2012-09-19 | 益普生制药股份有限公司 | Process for the synthesis of Ac-Arg-Cyclo(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 |
US9314509B2 (en) | 2009-11-16 | 2016-04-19 | Ipsen Pharma S.A.S. | Pharmaceutical compositions of melanocortin receptor ligands |
CN102665401A (en) * | 2009-11-16 | 2012-09-12 | 益普生制药股份有限公司 | Pharmaceutical compositions of melanocortin receptor ligands |
WO2011060355A1 (en) * | 2009-11-16 | 2011-05-19 | Ipsen Pharma S.A.S | Process for the synthesis of ac-arg-cyclo(cys-d-ala-his-d-phe-arg-trp-cys)-nh2 |
RU2548753C2 (en) * | 2009-11-16 | 2015-04-20 | Ипсен Фарма С.А.С. | Pharmaceutical compositions of melanocortin receptor ligands |
WO2011060352A1 (en) * | 2009-11-16 | 2011-05-19 | Ipsen Pharma S.A.S. | Pharmaceutical compositions of melanocortin receptor ligands |
US10017539B2 (en) | 2009-11-23 | 2018-07-10 | Palatin Technologies, Inc. | Melanocortin-1 receptor-specific cyclic hexapeptides |
US9580466B2 (en) | 2009-11-23 | 2017-02-28 | Palatin Technologies, Inc. | Melanocortin-1 receptor-specific linear peptides |
US8933194B2 (en) | 2009-11-23 | 2015-01-13 | Palatin Technologies, Inc. | Melanocortin-1 receptor-specific linear peptides |
US10711039B2 (en) | 2009-11-23 | 2020-07-14 | Palatin Technologies, Inc. | Melanocortin receptor-specific peptide with C-terminal naphthylalanine |
US10106578B2 (en) | 2009-11-23 | 2018-10-23 | Palatin Technologies, Inc. | Melanocortin-1 receptor-specific linear peptides |
WO2012172433A2 (en) | 2011-06-14 | 2012-12-20 | Ipsen Pharma S.A.S. | A sustained-release composition containing peptides as active ingredient |
US9845339B2 (en) | 2011-12-29 | 2017-12-19 | Rhythm Pharmaceuticals, Inc. | Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers |
US11702448B2 (en) | 2011-12-29 | 2023-07-18 | Rhythm Pharmaceuticals, Inc. | Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers |
US10167312B2 (en) | 2011-12-29 | 2019-01-01 | Rhythm Pharmaceuticals, Inc. | Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers |
WO2013102047A1 (en) | 2011-12-29 | 2013-07-04 | Rhythm Pharmaceuticals, Inc. | Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers |
EP3988108A1 (en) | 2011-12-29 | 2022-04-27 | Rhythm Pharmaceuticals, Inc. | Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers |
US10954268B2 (en) | 2011-12-29 | 2021-03-23 | Rhythm Pharmaceuticals, Inc. | Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers |
EP3539551A1 (en) | 2011-12-29 | 2019-09-18 | Rhythm Pharmaceuticals, Inc. | Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers |
EP2705835A1 (en) | 2012-06-08 | 2014-03-12 | Ipsen Pharma S.A.S. | Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release |
US9951116B2 (en) | 2012-10-19 | 2018-04-24 | Txp Pharma Gmbh | Alpha- and gamma-MSH analogues |
US10196425B2 (en) | 2013-03-15 | 2019-02-05 | Rhythm Pharmaceuticals, Inc. | Peptide compositions |
US11129869B2 (en) | 2013-03-15 | 2021-09-28 | Rhythm Pharmaceuticals, Inc. | Pharmaceutical compositions |
WO2014144260A1 (en) * | 2013-03-15 | 2014-09-18 | Rhythm Metabolic, Inc. | Peptide compositions |
RU2725150C2 (en) * | 2013-03-15 | 2020-06-30 | Ритм Фармасьютикалз, Инк. | Peptide compositions |
AU2014227712B2 (en) * | 2013-03-15 | 2018-08-02 | Rhythm Pharmaceuticals, Inc. | Peptide compositions |
US10858399B2 (en) | 2013-03-15 | 2020-12-08 | Rhythm Pharmaceuticals, Inc. | Peptide compositions |
AU2019200101B2 (en) * | 2013-03-15 | 2021-02-04 | Rhythm Pharmaceuticals, Inc. | Pharmaceutical Compositions |
WO2014144842A3 (en) * | 2013-03-15 | 2015-04-09 | Rhythm Metabolic, Inc. | Pharmaceutical compositions |
US11141455B2 (en) | 2014-04-22 | 2021-10-12 | Txp Pharma Gmbh | Peptide analogues with branched amino acid probe(s) |
US10960046B2 (en) | 2015-09-30 | 2021-03-30 | Rhythm Pharmaceuticals, Inc. | Method of treating melanocortin-4 receptor pathway-associated disorders |
EP4029513A1 (en) | 2015-09-30 | 2022-07-20 | Rhythm Pharmaceuticals, Inc. | Melanocortin-4 receptor agonists for the treatment of disorders characterised by pomc gene hypermethylation |
WO2018167194A1 (en) * | 2017-03-15 | 2018-09-20 | Novo Nordisk A/S | Bicyclic compounds capable of binding to melanocortin 4 receptor |
WO2019195756A1 (en) | 2018-04-06 | 2019-10-10 | Rhythm Pharmaceuticals, Inc. | Compositions for treating kidney disease |
WO2019219714A1 (en) * | 2018-05-15 | 2019-11-21 | Novo Nordisk A/S | Compounds capable of binding to melanocortin 4 receptor |
WO2022067086A1 (en) * | 2020-09-24 | 2022-03-31 | Rhythm Pharmaceuticals, Inc. | Methods of treating melanocortin-4 receptor pathway-associated disorders |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220127305A1 (en) | Melanocortin receptor ligands | |
US8349797B2 (en) | Ligands of melanocortin receptors | |
US20100173834A1 (en) | Cyclic peptide melanocortin receptor ligands |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680032423.5 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 188545 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2008520417 Country of ref document: JP Kind code of ref document: A Ref document number: 2614615 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006269261 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 208/KOLNP/2008 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 565217 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2006269261 Country of ref document: AU Date of ref document: 20060710 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006786665 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008104803 Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11988533 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201732 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020097022845 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 246392 Country of ref document: IL |